孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床观察
TITLE:
摘要: 目的:观察孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床疗效及安全性。方法:选取2016年1-12月宁波市鄞州区钱湖医院门诊收治的急性细菌性支气管炎咳嗽患者139例,按照随机数字表法分为对照组(69例)与观察组(70例)。对照组患者给予盐酸莫西沙星片0.4 g,po,qd;观察组患者在对照组基础上给予孟鲁司特钠片10 mg,po,每晚1次。两组患者疗程均为6 d。比较两组患者治疗前后的咳嗽症状评分、外周血白细胞计数(WBC)和C反应蛋白(CRP)含量,观察临床疗效、不良反应发生情况和临床转归情况。结果:治疗前,两组患者的咳嗽症状评分、外周血WBC和CRP含量比较,差异均无统计学意义(P>0.05)。治疗后,两组患者的咳嗽症状评分、外周血WBC和CRP含量均较治疗前显著降低,且观察组治疗3 d后的咳嗽症状评分显著低于同期对照组,差异均有统计学意义(P<0.05);但治疗6 d后两组患者上述各项指标比较,差异均无统计学意义(P>0.05)。观察组患者的治愈率为64.29%,显著高于对照组的44.93%,差异有统计学意义(P<0.05);观察组和对照组患者的有效率分别为97.14%和97.10%,组间比较差异无统计学意义(P>0.05)。两组患者治疗期间均未见明显不良反应发生,且临床转归良好。结论:孟鲁司特联合莫西沙星不但可有效地减轻急性细菌性支气管炎患者的咳嗽症状和炎症反应,还可明显提高治愈率,且安全性较高。
ABSTRACT: OBJECTIVE: To observe clinical efficacy and safety of montelukast combined with moxifloxacin in the treatment of cough of acute bacterial bronchitis. METHODS: A total of 139 cases of cough of acute bacterial bronchitis selected from outpatient department of Ningbo Yinzhou District Qianhu Hospital during Jan.-Dec. 2016 were divided into control group (69 cases) and observation group (70 cases) according to random number table. Control group was given Moxifloxacin hydrochloride tablets 0.4 g, po, qd; observation group was additionally given Montelukast sodium tablets 10 mg, po, once every night, on the basis of control group. Both groups were treated for 6 d. Cough symptom scores, peripheral blood WBC and CRP contents were compared between 2 groups before and after treatment. Clinical efficacies, the occurrence of ADR and clinical outcome were observed in 2 groups. RESULTS: Before treatment, there was no statistical significance in cough symptom scores, peripheral blood WBC or CRP contents between 2 groups (P>0.05). Compared to before treatment, cough symptom scores, peripheral blood WBC and CRP contents of 2 groups were decreased significantly after treatment, and the cough symptom score of observation group after 3 d of treatment was significantly lower than that of control group at the same time, with statistical significance (P<0.05). There was no statistical significance in above indexes between 2 groups after 6 d of treatment (P>0.05). Cure rate of observation group was 64.29%, which was significantly higher than 44.93% of control group, with statistical significance (P<0.05). Response rates of observation group and control group were 97.14% and 97.10%, there was no statistical significance (P>0.05). No ADR was found in 2 groups during treatment, and good clinical outcome was obtained. CONCLUSIONS: Montlukast combined with moxifloxacin not only relieve cough symptom and inflammation, but also improve cure rate significantly with good safety.
期刊: 2017年第28卷第29期
作者: 王龙,丁群力,马红映,梁小飞,邓在春
AUTHORS: WANG Long,DING Qunli,MA Hongying,LIANG Xiaofei,DENG Zaichun
关键字: 急性细菌性支气管炎;咳嗽;孟鲁司特;莫西沙星
KEYWORDS: Acute bacterial bronchitis; Cough; Montelukast; Moxifloxacin
阅读数: 67 次
本月下载数: 4 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!